Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

Unresectable or Metastatic Melanoma Clinical Trial

Official title:
A Phase 3, Randomized, Double-Blind Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab Versus Ipilimumab Monotherapy in Subjects With Previously Untreated Unresectable or Metastatic Melanoma

Status Active, not recruiting

Clinical Trial Summary

The purpose of this study is to show that Nivolumab and/or Nivolumab in combination with Ipilimumab will extend progression free survival and overall survival compared to Ipilimumab alone.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Melanoma
Unresectable or Metastatic Melanoma

Clinical Trial Details

NCT number	NCT01844505
Study type	Interventional
Source	Bristol-Myers Squibb
Contact
Status	Active, not recruiting
Phase	Phase 3
Start date	June 11, 2013
Completion date	October 31, 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT06359860` - A Study of ST-1898 for Unresectable or Metastatic Melanoma	Phase 1/Phase 2
Terminated	`NCT03993379` - PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors	Phase 2
Terminated	`NCT01810016` - NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma	Phase 1
Active, not recruiting	`NCT05783882` - Prolgolimab 250 mg Q3W in Patients With Unresectable or Metastatic Melanoma	Phase 3
Completed	`NCT01721746` - A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)	Phase 3
Recruiting	`NCT04674683` - Study Comparing Investigational Drug HBI-8000 Combined With Nivolumab vs. Nivolumab in Patients With Advanced Melanoma	Phase 3